Health Care • Biotechnology: Pharmaceutical Preparations
$38.90 ▼ -0.01
(-0.03%)
MKT CAP: $4.22B • VOL: 967.6K
52W L $17 52W H $49
EWTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $535.9M | $444.7M | $320.2M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$191.4M | -$158.8M | -$114.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$167.8K | -$133.8K | -$100.2K |
| EBITDA (Normalized) | -$191.2M | -$157.8M | -$114.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$143.8M | -$109.0M | -$91.9M |
| Capital Expenditures (CapEx) | $256.0K | $1.3M | $0 |
| Free Cash Flow (FCF) | -$144.1M | -$110.3M | -$91.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -31.8% | -29.2% | -6.4% |
| Cash & Short-Term Equivalents | $61.1M | $41.7M | — |
| Total Debt (Short + Long Term) | $13.7M | $12.4M | $543.9M |
| Total Stockholders' Equity | $522.3M | $459.2M | $1.12B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EWTX.